(RXRX) Recursion Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RXRX) Recursion Pharmaceuticals, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Recursion Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to access the complete ready-to-use report instantly.
Stars
REC-994, Phase IIa
REC-994 is Recursion Pharmaceuticals, Inc.'s most advanced named asset, now in Phase IIa for cerebral cavernous malformation, a rare disease with no approved disease-modifying therapy. That makes it a high-value shot on goal in an area where even small positive data can matter a lot. If the next readout stays positive, REC-994 is one of the clearest near-term upside drivers for Recursion Pharmaceuticals, Inc.
REC-3599, Phase I
REC-3599 is a Phase I, clinical-stage GM2 gangliosidosis program for Recursion Pharmaceuticals, Inc., with zero current market share and no approved disease-modifying therapy. Early human data can re-rate the asset fast because even a small responder base in this ultra-rare space can shift value. That makes it a high-growth, high-support BCG "Star" profile.
REC-4881, clinical-stage
REC-4881 is a clinical-stage asset aimed at familial adenomatous polyposis, a rare disease seen in about 1 in 8,000 to 1 in 10,000 births. That puts it in a high-unmet-need niche where a clear clinical win could give Recursion Pharmaceuticals, Inc. a strong specialty position. It is still capital hungry, though, so the program needs ongoing R&D spend and trial support.
REC-2282, clinical-stage
REC-2282 is a clinical-stage NF2 pipeline asset for Recursion Pharmaceuticals, targeting a rare disease that affects about 1 in 25,000 to 33,000 people. With limited current treatment options, a clear efficacy and safety signal could support fast uptake and make it a strong BCG Stars candidate. If approved, it has the profile of a future commercial leader in a small but high-value market.
- Rare disease, high unmet need
- Limited competition today
- Approval could drive rapid scaling
AI-enabled drug discovery platform
Recursion Pharmaceuticals, Inc.’s AI-enabled drug discovery platform is the company’s main Star: it blends biology, chemistry, automation, data science, and engineering into one engine for pipeline creation. In 2025, this platform stayed central to R&D, with Recursion reporting cash, cash equivalents, and marketable securities of $610.4 million at year-end, supporting continued investment.
It is a growth asset because output depends on steady spend on data, compute, and lab scale-up, not just one-off wins. That makes it the base for future programs and partnerships, but it also means margins stay pressured until more candidates move through the pipeline.
- Core differentiated drug discovery engine
- Needs ongoing capital to scale
- Supports future pipeline creation
- Still in growth investment mode
Recursion’s AI-Driven Rare-Disease Stars Have a Well-Funded Runway
Recursion Pharmaceuticals, Inc.’s Stars are its late-stage rare-disease assets and AI platform: REC-994 (Phase IIa), REC-3599 (Phase I), REC-4881 (clinical), REC-2282 (clinical), and the Recursion Pharmaceuticals, Inc. platform. At 2025 year-end, Recursion Pharmaceuticals, Inc. held $610.4 million in cash, cash equivalents, and marketable securities, keeping these growth bets funded.
| Star | Stage | Why it fits |
|---|---|---|
| REC-994 | Phase IIa | Lead near-term upside |
| Platform | Core engine | Funds pipeline growth |
What is included in the product
Detailed Word Document
Recursion Pharmaceuticals’ BCG Matrix maps its AI drug pipeline for where to invest, hold, or divest.
Editable Excel File
Quick BCG Matrix snapshot for Recursion Pharmaceuticals, Inc. that highlights pain points and portfolio priorities at a glance.
Reference Sources
Provides a credible source trail for Recursion Pharmaceuticals, Inc., helping investors verify key claims and make faster, better decisions.
Cash Cows
No marketed drug revenue
Recursion Pharmaceuticals, Inc. is still clinical-stage, so it has no approved drug and no marketed product revenue to act as a true cash cow. In its latest reported year, the company still relied on collaboration and funding income rather than sales, with revenue mainly from partnerships. That means cash generation is strategic, not product-led, and the BCG cash-cow bucket is effectively empty.
Bayer AG collaboration
Recursion Pharmaceuticals, Inc.'s Bayer AG collaboration is a cash cow-like asset because it monetizes the platform without a launched drug. The 2019 pact targeted up to $1.2 billion in milestones plus research funding and royalties, with Bayer paying upfront and ongoing discovery support. That kind of external income helps offset Recursion Pharmaceuticals, Inc.'s 2025 net loss of $560.4 million and reduces dependence on product sales.
Takeda Pharmaceutical collaboration
Recursion Pharmaceuticals, Inc.'s Takeda Pharmaceutical collaboration is a non-dilutive funding source that helps pay for R and D without adding share dilution. It brings in collaboration revenue tied to partnered programs, so Recursion is less dependent on any single internal asset to fund operations. In BCG terms, this is the closest thing to a cash cow: low-growth, but cash-positive and strategic.
University of Utah Research Foundation agreement
The University of Utah Research Foundation agreement is a low-cost cash-supporting asset for Recursion Pharmaceuticals, Inc. Academic licensing can bring recurring fees and external validation without the spend of a full internal program. For a pre-commercial biotech, that kind of non-dilutive support helps offset R&D burn.
It is unlikely to move revenue much on its own, but it can steady the base while Recursion scales its pipeline. The real value is cheap maintenance, data access, and credibility with partners.
- Recurring fees
- Low upkeep cost
- External validation
- Supports pre-commercial cash flow
Ohio State Innovation Foundation agreement
The Ohio State Innovation Foundation agreement gives Recursion Pharmaceuticals, Inc. another non-dilutive support channel, so it can widen its research network without matching that growth with direct commercialization spend. In BCG terms, this looks more like a steady funding stream than a cash-heavy development asset, especially since Recursion reported $1.0 billion in cash, cash equivalents, and marketable securities as of Q1 2025.
- External scientific support
- Lower direct burn
- Steadier funding profile
Recursion’s “Cash Cows” Are Really Partnerships, Not Products
Recursion Pharmaceuticals, Inc. has no true cash cows because it remains pre-commercial and depends on collaboration revenue, not product sales. Its closest cash-cow-like assets are Bayer AG and Takeda Pharmaceutical partnerships, which bring non-dilutive funding that helps offset the 2025 net loss of $560.4 million.
| Metric | Value |
|---|---|
| Q1 2025 cash | $1.0 billion |
| 2025 net loss | $560.4 million |
| Cash cow status | None |
Preview Before You Purchase
Recursion Pharmaceuticals, Inc. Reference Sources
You're previewing the exact Recursion Pharmaceuticals, Inc. BCG Matrix report you'll receive after purchase. The file is the same final document—fully formatted, ready to use, and free of demo content or watermarks. Once purchased, it’s instantly available for download and immediate application in your analysis, presentation, or strategy planning.
Dogs
No approved products
Recursion Pharmaceuticals, Inc. had no approved products in the set, so there was no marketed therapeutic franchise to classify as a commercial Dog. Without an approved asset, there is no mature market share or durable product cash flow to harvest or exit; 2025 revenue was still driven by collaboration income, not product sales. That keeps Recursion Pharmaceuticals, Inc. in a pipeline-only state, with no true Dog to manage.
No recurring product sales
Recursion Pharmaceuticals, Inc. still has no recurring product sales, so it cannot use a mature cash cow to fund growth. The latest filings show revenue comes from collaborations, not a commercial product base, which is a structural drag in BCG terms. With no legacy brand to harvest, each program still depends on R&D spend and future approvals.
High R and D cash burn
Recursion Pharmaceuticals, Inc. spent about $395 million on R&D in 2024, while revenue was only about $58 million, so cash burn far outpaced cash generation. The company also reported a net loss of about $718 million, which shows how clinical and preclinical work can drain capital long before products reach market. In BCG terms, this fits a dog profile when assets do not move forward fast enough to offset the burn.
Early-stage competitive programs
Recursion Pharmaceuticals, Inc. has several early-stage competitive programs that are still preclinical, so they have not yet shown human efficacy. In crowded fields, low share can stick for years, and the math is harsh: one weak readout can erase years of optionality. If new data do not improve, these assets can become value traps rather than BCG-style "Dogs".
- Preclinical only; no human efficacy yet
- Crowded markets can delay share gains
- Weak data can trap capital for years
Pre-commercial biotech model
Recursion Pharmaceuticals, Inc. is still pre-commercial, so most value is tied to pipeline progress, not product sales. That keeps the model dependent on outside capital and partner funding, and unvalidated programs still carry a dog-like downside until approvals land. Latest filings still show heavy R&D spend and no mature launch revenue base, so execution risk remains high.
- Pre-commercial, not scale commercial
- Partner cash matters most
- R&D burn drives dilution risk
- Approval is the key value trigger
Recursion Has No Dog—Just Heavy Burn and No Product Sales
Recursion Pharmaceuticals, Inc. has no marketed drug, so it has no true Dog to harvest in BCG terms. FY2025 revenue was about $58 million, while FY2024 R&D spend was about $395 million and net loss about $718 million, showing heavy burn and no cash-generating legacy asset.
| FY2025 | FY2024 |
|---|---|
| Revenue: $58M | R&D: $395M |
| No product sales | Net loss: $718M |
Question Marks
REC-3964, preclinical
REC-3964 is a preclinical bet on Clostridium difficile colitis, a high-need space with about 500,000 U.S. infections and roughly 29,000 deaths a year. It has no human market share yet, so the asset is still a pure Question Mark in the BCG Matrix. Recursion must keep funding heavy R&D before any commercial case is clear.
REC-64917, preclinical
REC-64917 is a preclinical bet on neural or systemic inflammation, a scientifically attractive area but still far from proof. At this stage, the odds are tough: industry data show preclinical programs have less than a 10% chance of reaching approval. It can only move from question mark to star if Recursion Pharmaceuticals, Inc. gets strong human safety and efficacy data in the clinic.
REC-65029, preclinical
REC-65029 is a classic question mark: it is preclinical, targets HRD-negative ovarian cancer, and has zero share or revenue today. Ovarian cancer remains a large unmet market, with about 324,000 new cases worldwide each year, but competition is crowded and the clinical bar is high, so Recursion Pharmaceuticals, Inc. must prove strong efficacy fast or prune it.
REC-648918, preclinical
REC-648918 is a Question Mark: it is built to boost anti-tumor immunity, but it is still preclinical, so there is no human proof yet. The oncology market is huge—global cancer drug sales were about $223 billion in 2024—and that makes the prize real, but it also means the bar is high.
Recursion Pharmaceuticals, Inc. must fund expensive preclinical work, IND-enabling studies, and early trials before the asset can move from concept to share.
- Preclinical; no clinical data yet
- Immune-oncology angle, high upside
- Needs heavy capital to advance
REC-2029, preclinical
REC-2029 is a preclinical bet on wnt-mutant hepatocellular carcinoma, a niche with real upside because liver cancer still causes about 865,000 new cases and 760,000 deaths a year worldwide. But it is still unproven, so the asset sits squarely in the Question Mark bucket: high growth potential, no clinical proof yet, and a real risk of failure.
For Recursion Pharmaceuticals, Inc., REC-2029 can scale fast only if early biology turns into clear human data; until then, it adds optionality, not earnings. In BCG terms, it is a high-risk, high-reward program with no sales today and no visible path to near-term cash flow.
- Preclinical, no human proof yet
- Targets wnt-mutant hepatocellular carcinoma
- High unmet need, but high failure risk
- Potentially large upside if validated
Recursion’s Preclinical Pipeline: High Upside, High Risk
Recursion Pharmaceuticals, Inc.'s Question Marks are all preclinical, so they have no revenue, no market share, and need heavy cash burn before proof. That makes them high-upside but high-failure assets. In 2025/2026, they are still value drivers only if early data turn into human efficacy.
| Program | Status | Fit |
|---|---|---|
| REC-3964 | Preclinical | CDI |
| REC-64917 | Preclinical | Inflammation |
| REC-65029 | Preclinical | Ovarian cancer |
| REC-648918 | Preclinical | Immuno-oncology |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.